|
Market Closed -
Australian S.E.
09:13:31 30/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 13.13 AUD | -2.60% |
|
-3.88% | +17.23% |
Company Valuation: Telix Pharmaceuticals Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 2,209 | 2,300 | 3,263 | 8,238 | 3,794 | 4,461 | - | - |
| Change | - | 4.1% | 41.89% | 152.44% | -53.95% | 17.6% | - | - |
| Enterprise Value (EV) 1 | 2,187 | 2,187 | 3,149 | 8,098 | 4,167 | 4,990 | 4,951 | 4,933 |
| Change | - | -0.02% | 44.01% | 157.15% | -48.55% | 19.76% | -0.78% | -0.36% |
| P/E | -27.2x | -21.7x | 626x | 170x | -375x | 197x | 2,336x | 55.1x |
| PBR | 1,024x | 28.7x | 21.9x | 14.5x | 6.43x | 4.79x | 6.3x | 5.74x |
| PEG | - | -1.2x | -6x | 0x | 3x | -1x | -25.5x | 0x |
| Capitalization / Revenue | 291x | 14.4x | 6.49x | 10.5x | 3.17x | 3.21x | 2.84x | 2.41x |
| EV / Revenue | 288x | 13.7x | 6.27x | 10.3x | 3.48x | 3.59x | 3.15x | 2.67x |
| EV / EBITDA | -31.2x | -32.3x | 53.9x | 81.6x | 74.4x | 56.7x | 61.3x | 29.5x |
| EV / EBIT | -29.1x | -29.9x | 60.9x | 88.7x | 98.7x | 90x | 108x | 38.3x |
| EV / FCF | -35.2x | -29.9x | 223x | 282x | -68.4x | 233x | -968x | 57.3x |
| FCF Yield | -2.84% | -3.35% | 0.45% | 0.35% | -1.46% | 0.43% | -0.1% | 1.75% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.285 | -0.335 | 0.0161 | 0.1446 | -0.0299 | 0.0666 | 0.00562 | 0.2384 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7.596 | 160.1 | 502.5 | 783.2 | 1,198 | 1,391 | 1,573 | 1,848 |
| EBITDA 1 | -70.07 | -67.8 | 58.44 | 99.28 | 55.98 | 88 | 80.72 | 167.4 |
| EBIT 1 | -75.25 | -73.18 | 51.69 | 91.26 | 42.23 | 55.45 | 46 | 128.7 |
| Net income 1 | -80.51 | -104.1 | 5.211 | 49.92 | -10.1 | 27.02 | 2.508 | 81.51 |
| Net Debt 1 | -22.02 | -113 | -114.1 | -139.5 | 372.9 | 528.6 | 489.6 | 471.7 |
| Reference price 2 | 7.75 | 7.27 | 10.08 | 24.61 | 11.20 | 13.13 | 13.13 | 13.13 |
| Nbr of stocks (in thousands) | 285,073 | 316,343 | 323,727 | 334,724 | 338,721 | 339,784 | - | - |
| Announcement Date | 23/02/22 | 27/02/23 | 22/02/24 | 20/02/25 | 19/02/26 | - | - | - |
1AUD in Million2AUD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 202.52x | 3.67x | 58.05x | -.--% | 3.22B | |
| 16.97x | 6.42x | 12.3x | 1.76% | 64.38B | |
| 30.03x | 8.21x | 26.91x | 0.04% | 56.16B | |
| 37.32x | 6.62x | 19.78x | 0.87% | 54.16B | |
| 35.94x | 3.4x | 14.66x | -.--% | 45.33B | |
| 49.01x | 5.65x | 30.93x | -.--% | 42.25B | |
| -19.75x | 191.25x | -21.04x | -.--% | 40.78B | |
| 46.05x | 8.16x | 27.33x | -.--% | 33.8B | |
| 31.61x | 8.04x | 20.91x | 0.41% | 32.25B | |
| 27.18x | 5.72x | 14.84x | -.--% | 23.57B | |
| Average | 45.69x | 24.71x | 20.47x | 0.31% | 39.59B | |
| Weighted average by Cap. | 29.21x | 25.53x | 16.73x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TLX Stock
- Valuation Telix Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
